Acute inferior myocardial infarction in a young man with testicular seminoma: A case report

paythelady.612 shared this article with you from Inoreader Acute inferior myocardial infarction in a young man with testicular seminoma: A case report Μέσω pubmed: "world j clin cases"... World J Clin Cases. 2021 Jun 6;9(16):4040-4045. doi: 10.12998/wjcc.v9.i16.4040. ABSTRACT BACKGROUND: Atherosclerosis represents the main cause of myocardial infarction (MI); other causes such as coronary embolism, vasospasm, coronary-dissection or drug use are much rarely encountered, but should be considered in less common clinical scenarios. In young individuals without cardiovascular risk factors, the identification of the cause of MI can sometimes be found in the medical history and previous treatments undertaken. CASE SUMMARY: We present the case of a 34-year-old man presenting acute inferior ST-elevation MI without classic cardiac risk factors. Seven years ago, he suffered from orchidopexy for bilateral cryptorchidism, and was recently diagnosed with right testicular seminoma for which he had to undergo surgical resection and chemotherapy with bleomycin, etoposide and cisplatin. Shortly after the first chemotherapy treatmen t, namely on day five, he suffered an acute MI. Angiography revealed a mild stenotic lesion at the level of the right coronary artery with suprajacent thrombus and vasospasm, with no other significant lesions on the other coronary arteries. A conservative treatment was decided upon by the cardiac team, including dual antiplatelets therapy and anticoagulants with good further evolution. The patient continued the chemotherapy treatment according to the initial plan without other cardiovascular events. CONCLUSION: In young individuals with no cardiovascular risk factors undergoing aggressive chemotherapy, an acute MI can be caused by vascular toxicity of several anti-cancer drugs. PMID:34141764 | PMC:PMC8180225 | DOI:10.12998/wjcc.v9.i16.4040 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.